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Single low-dose primaquine to reduce malaria 
transmission 
The WHO Evidence Review Group’s August, 
2012 report about the safety and eﬀ ectiveness 
of a single dose of primaquine as a Plasmodium 
falciparum gametocytocide1 and WHO’s new policy 
recommendation about low-dose primaquine2,3 
generated much interest for malaria control 
programmes seeking additional methods to reduce 
malaria transmission, especially in settings in which 
elimination of malaria is pursued. A single dose of 
primaquine at 0·75 mg base per kg has long been 
recommended as an adjunct therapy to reduce malaria 
transmission of P falciparum. However, the drug is 
often not used because of concerns about dose-
dependent haemolytic eﬀ ects in patients with glucose-
6-phosphate dehydrogenase (G6PD) deﬁ ciency and 
the low availability of G6PD tests in the ﬁ eld. WHO’s 
expert review group reviewed the available scientiﬁ c 
literature, which suggested that one low dose of 
0·25 mg base per kg of primaquine could be used 
widely and safely in people with malaria infection, 
including those with G6PD deﬁ ciency,1 to help reduce 
the duration of circulating late-stage gametocytes 
(the sexual transmissible stage of the parasite) by 
roughly half and contribute to malaria transmission 
reduction. The authors of the report noted that 
additional eﬀ ectiveness and safety evidence would be 
welcome to characterise the optimum dose and help 
countries to establish policies and strategies for single 
low-dose primaquine.1 
In The Lancet Infectious Diseases, Alice Eziefula 
and colleagues describe the results of the ﬁ rst 
formal dose-ﬁ nding study to assess the P falciparum 
gametocytocidal eﬃ  cacy (measured as duration of 
gametocyte carriage) of a single dose of primaquine 
when given with artemisinin combination therapy.4 
The study included 468 Ugandan children younger 
than 10 yea rs with normal G6PD function and 
uncomplicated malaria who received standard doses 
of artemether–lumefantrine and one low dose of 
primaquine at doses of 0·75 mg/kg, 0·4 mg/kg, and 0·1 
mg/kg. The aim was to establish the lowest eﬃ  cacious 
dose in people with normal G6PD enzyme function. All 
doses of primaquine were safe and very well tolerated. 
The 0·4 mg/kg dose and the standard 0·75 mg/kg 
regimen had similar gametocytocidal eﬃ  cacy (mean 
duration of gametocyte carriage: 6·6 days in the 0·75 
mg/kg group and 6·3 days in the 0·4 mg/kg group), 
but an eﬃ  cacy gradient was apparent from 0·4 mg/
kg to 0·1 mg/kg to placebo. As Eziefula and colleagues 
note, this work preceded the choice of 0·25 mg/kg in 
the WHO report,2 but the WHO-recommended dose 
falls between the 0·4 mg/kg and 0·1 mg/kg doses 
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assessed. In malaria control programme settings, 
children are likely to receive a speciﬁ c number of 
tablets within prespeciﬁ ed age or bodyweight bands, 
whereby actual doses will range above and below the 
intended target dose of 0·25 mg/kg (eg, 0·15–0·35 
or 0·1–0·4 mg/kg).5 Eziefula and colleagues’ study 
clariﬁ es, for the ﬁ rst time, that doses greater than 
0·4 mg/kg are not needed but, as the authors note, 
further attention should be given to the eﬃ  cacy 
gradient between 0·4 mg/kg and 0·1 mg/kg, including 
the assessment of their safety in patients with G6PD 
deﬁ ciency to deﬁ ne the most eﬃ  cacious and safest 
primaquine treatment regimen. Several studies are 
planned or in progress, and although protocol changes 
can be diﬃ  cult, investigators should strongly consider 
including groups that would allow assessment of 
the dosing based on these new ﬁ ndings and WHO’s 
recommendations. 
The investigators gave the primaquine dose to the 
participants on day 2, which is common practice.6 
Nevertheless, national malaria control programmes 
might be more inclined to give primaquine with 
the ﬁ rst dose of the ACT to ensure that both drugs 
are given under observation. Although the authors 
acknowledged the limitation of delaying the 
primaquine dose, this approach was used to minimise 
potential interference of the malaria-attributable 
haematological eﬀ ects during the acute phase of 
illness. However, the optimum timing of the single 
dose deserves further study. Primaquine has a very 
short half-life and delay of its administration has been 
suggested to enhance its eﬃ  cacy because gametocyte 
densities often peak several days after the start of 
artemisinin treatment.7,8 Delayed dosing might also 
improve safety because the risk of haemolysis in 
G6PD-deﬁ cient patients could be lower in afebrile 
patients.9 However, it is unclear whether this beneﬁ t 
is outweighed by the additional days of potential 
infectivity before primaquine administration6 and 
the reduced opportunity to give primaquine under 
observation. 
A ﬁ nal programmatic consideration is the adherence 
to the full 3 day course of the artemisinin combination 
therapy. Artemether–lumefantrine, which resulted in 
clearance of the asexual parasites, was also an eﬀ ective 
treatment for the sexual stage of the parasites, which 
is consistent with earlier studies with other artemisinin 
combination therapies.6 A substantial decrease 
was recorded in the nucleic acid sequence-based 
ampliﬁ cation-measured gametocyte prevalence from 
roughly 82% at day 0 to roughly 40% at day 2 before 
primaquine administration, and to 15% by day 14 in 
participants who received artemether–lumefantrine 
plus placebo. Although complete gametocyte 
clearance was not achieved, this ﬁ nding emphasises 
the importance of eﬀ ective artemisinin combination 
therapy treatment, since slow or incomplete clearance 
of the asexual stages of the parasite could fuel 
gametocyte numbers and viability.6,10 Mass malaria 
treatment campaigns must focus on ensuring that 
full dosing of artemisinin combination therapy is 
achieved. To this end, we will all welcome a safe and 
highly eﬀ ective single-dose treatment that can be 
combined with one dose of primaquine and can be 
given as directly observed treatment for malaria.
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